Replies to post #436954 on Anavex Life Sciences Corp (AVXL)

[LBSR TO DA MOON]

How about the possibility that AVXL is seeking to enter into a partnership with a BP so that this potential AD prophylactic trial could be accomplished much faster?

Given the findings here and the earlier successful 3-71 Phase 1 safety study, Anavex may be readying an advanced 3-71 AD prophylactic trial.

[ExtremelyBullishZig]

Probably because it is easier to fake not getting dementia than it is to fake treating and curing it.

[rx7171]

Unfortunately in order to prove a preventive hypothesis it will require a large very lengthy placebo controlled trial since AD progression at the early stage is a multi year process.
Best hope is approval for AD then off label prescription for prevention.

I’d be happy to add it to my daily blood pressure med.

[Steady_T]

Not a chance. 3-71 will have to go through a P2 trial to demonstrate dosing effectiveness for a specific disease, likely to be AD. It will be tested in people that have been diagnosed with AD to show effectiveness.

Only then would Anavex even begin to consider a trial for prophylactic use. Even then it would probably not be tested until some of the new AD diagnostic tests become available that will detect AD pathology before a person shows any symptoms.

Such a trial would require a large number of subjects and be multiple years long. Anavex has better options in choosing trials to get 3-71 on the market.

Once 3-71 is on the market conducting a prophylactic trial makes sense. The same goes for 2-73 and generalized aging use.

[Investor2014]

That's not how it works.